Prescription drug · ANDA
Allopurinol NDC 0904-7041
Allopurinol 100 mg/1 · Tablet · Oral · Major Pharmaceuticals
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0904-7041-61 | 00904704161 | 100 BLISTER PACK in 1 CARTON (0904-7041-61) / 1 TABLET in 1 BLISTER PACKMarketed from Feb 8, 2018 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Allopurinol
- Generic name (nonproprietary)
- allopurinol
- Active ingredients
- Allopurinol — 100 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- Major Pharmaceuticals
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 210117
- Marketing start
- Listing expires
- Other FDA classes
- Xanthine Oxidase Inhibitors (Mechanism)
- Identifiers
- Product ID 0904-7041_85b84812-5e4e-4a80-8757-c5ef08d15cfeSPL ID 85b84812-5e4e-4a80-8757-c5ef08d15cfeSPL set ID b630c1cb-d4b7-4f80-b252-5947c1887defRxCUI 197319UNII 63CZ7GJN5I
- Pharmacologic class
- Xanthine Oxidase Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N400904704161followed by a unit qualifier and the quantityPackage 00904-7041-61. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Allopurinol tablet is indicated for: • The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) • The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels • The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars a…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 210117
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Allopurinol | Allopurinol 200 mg/1 | TabletOral | Zydus Pharmaceuticals (USA) Inc. | 70710-2009 |
| Allopurinol | Allopurinol 100 mg/1 | TabletOral | Zydus Pharmaceuticals (USA) Inc. | 70710-1209 |
| Allopurinol | Allopurinol 300 mg/1 | TabletOral | Zydus Pharmaceuticals (USA) Inc. | 70710-1210 |
| Allopurinol | Allopurinol 300 mg/1 | TabletOral | Zydus Lifesciences Limited | 70771-1127 |
| Allopurinol | Allopurinol 100 mg/1 | TabletOral | Zydus Lifesciences Limited | 70771-1126 |
| Allopurinol | Allopurinol 100 mg/1 | TabletOral | Cardinal Health 107, LLC | 55154-2338 |
| Allopurinol | Allopurinol 200 mg/1 | TabletOral | Zydus Lifesciences Limited | 70771-1907 |